The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Long-term outcomes of patients with CLL treated with continuous ibrutinib
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, comments on the long-term outcomes of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. It has been reported that patients who have been able to maintain therapy on ibrutinib have a long-term survival that is comparable to healthy age-matched controls. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
